N/A N=119 Plasmodium Vivax Efficacy Trial in Cruzeiro do Sul, Acre, Brazil
Malaria
Primary: Number of Patients With Adequate Clearance of Parasites and Symptoms — 110 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=456 Pyronaridine Artesunate (3:1) in Children and Adults With Acute Plasmodium Vivax Malaria
Malaria
Primary: Crude Cure Rate on Day 14 — 217; 209; 75; 73 Participants
Phase 2 N=16 Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Vivax Malaria Vaccine Candidate PvDBPII in Matrix M1
Malaria, Vivax
Primary: Safety of the PvDBPII-Matrix M1 Vaccine Candidate, Assessed Through Collection of Data on the Frequency, Duration and Severity of Solicited and Unsolicited Adverse…
N/A N=254 Efficacy of 3 Regimens of Chloroquine and Primaquine for Treatment of P. Vivax Malaria, Cruzeiro do Sul, Acre, Brazil
P Vivax · Malaria, Vivax
Primary: Participants With Adequate Clinical and Parasitologic Response Among Patients Enrolled — 61; 88; 90 participants
Phase 1 N=2 Blood-Stage Plasmodium Vivax Cell Bank
Malaria
Primary: P. Vivax Blood Collection — 2 Participants
Phase 3 N=150 Efficacy and Safety Study of Tafenoquine (TQ) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax (P. Vivax) Malaria
Malaria, Vivax
Primary: Percentage of Participants With Relapse-free Efficacy at Six Months After Administration of Tafenoquine With DHA-PQP and DHA-PQP Alone — 12; 22 Percentage of…
Early Phase 1 N=6 VAC069: A Study of Blood-stage Controlled Human P. Vivax Infection
Malaria, Vivax
Primary: Number of Participants With Serious Adverse Events — 1 Participants
Phase 2 N=18 Evaluation of Reproducibility of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers
MALARIA · FEVER · Sweating Fever
Primary: Infection for P. Vivax — 11; 11; 9 days
Phase 4 N=156 Rigorous Assessment of P. Vivax Relapses and Primaquine Efficacy for Radical Cure
Vivax Malaria
Primary: Number of Patients Experiencing P. Vivax Recurrence — 48; 11; 2 Participants
Phase 2 N=81 Efficacy, Tolerability, PK of OZ439 in Adults With Acute, Uncomplicated P.Falciparum or Vivax Malaria Mono-infection
Malaria, Falciparum · Malaria, Vivax
Primary: Derived Parasite Reduction Rate at 24 Hours (PPR24) — 1.38; 1.56; 1.71; 1.63 Log10 parasites/24h — p=0.01
Phase 2 N=522 Ph 2B/3 Tafenoquine (TFQ) Study in Prevention of Vivax Relapse
Malaria, Vivax
Primary: Number of Participants With Recurrence-free Efficacy at 6 Months Post Dose — 35; 155; 83 Participants — p=<0.001
Phase 2 N=36 Study of VMP001 and AS01B (Adjuvant Formulation) in Healthy Malaria-Naïve Adults
Malaria · Plasmodium Vivax
Primary: Occurrence of Solicited Adverse Events Over a 7 Day Follow-up Period After Each Immunization (the Day of the Immunization and 6 Subsequent Days) During the Vaccination…
Phase 3 N=251 Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in Subjects With Plasmodium Vivax Malaria
Malaria, Vivax
Primary: Percentage of Participants With Clinically Relevant Hemolysis. — 2.41; 1.18 Percentage of participants
Phase 2 N=16 VAC071: A Study to Assess Efficacy of the ChAd63/MVA PvDBP Vaccines
Malaria, Vivax
Primary: Efficacy of the ChAd63 and MVA PvDBP Vaccines, Administered in a Heterologous Prime-boost Regimen, Assessed by a Reduced Parasite Multiplication Rate in Vaccinated…
Phase 2 N=22 Efficacy of SJ733 in Adults With Uncomplicated Plasmodium Falciparum or Vivax Malaria
Malaria, Falciparum · Malaria, Vivax
Primary: Crude Adequate Clinical and Parasitological Response (ACPR) — 90; 100 percentage of participants
Phase 2 N=60 A Pharmacokinetics, Safety and Efficacy Study of Tafenoquine (TQ) in Pediatric Subjects With Plasmodium Vivax (P. Vivax) Malaria
Malaria, Vivax
Primary: Area Under the Curve From Time 0 Extrapolated to Infinite Time (AUC[0-infinity]) of Tafenoquine by Weight Band in Participants Aged >=2 Years to <16 Years (Weighing >=5…
Phase 2 N=43 Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection
Malaria
Primary: Time to Parasite Clearance — 23.63; 44.97; 48.75 Hours
Phase 1 N=16 Study in Blood Stage Malaria Infection After DVI of Cryopreserved P. Falciparum (NF54 Strain) Sporozoites
Malaria,Falciparum · Parasitemia · Protozoan Infections
Primary: Incidence and Severity of Observed or Self-reported Adverse Events (AEs) Considered PfSPZ-DVI Challenge Inoculum-related. — 13; 12; 1; 2 Incidence
Phase 3 N=782 Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
Malaria
Primary: Number of Participants Who Deliver With a Composite Adverse Birth Outcome — 60; 54 Participants
N/A N=159 TES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014
Malaria · Falciparum Malaria · Vivax Malaria
Primary: Early Treatment Failure (ETF) — 0; 0 participants
Phase 1 N=22 DSM265 Chemoprophylaxis of Plasmodium Falciparum Malaria
Plasmodium Falciparum, Malaria
Primary: Infection Rate — 5; 6; 3; 0 Participants
Phase 1 N=6 Pyronaridine in Healthy Adult Participants Infected With Blood Stage Malaria
Malaria,Falciparum · Malaria · Malaria Recrudescence
Primary: Emax — 0.201 Maximum clearance rate (1/hour)
Phase 1 N=9 MMV533 Plasmodium Falciparum Volunteer Infection Study
Malaria
Primary: The Activity of Single Oral Doses of MMV533 (Name of Investigational Medicinal Product) on Clearance of Plasmodium — 42.17; 158.03; 187.57 PRR48=parasite reduction ratio…
Phase 3 N=1,271 Pyronaridine - Artesunate (3:1) Versus Mefloquine Plus Artesunate in Plasmodium Falciparum Malaria Patients
Falciparum Malaria
Primary: Percentage of Subjects With PCR-corrected Adequate Clinical and Parasitological Response (ACPR) on Day 28 — 99.2; 98.1 percentage of subjects — p=0.106
Phase 3 N=300 Reducing the Burden of Malaria in HIV-uninfected Pregnant Women and Infants
Malaria
Primary: Prevalence of Placental Malaria — 49; 30; 26 Participants
Phase 1 N=6 Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Infected With Blood Stage P. Falciparum
Infections · Vector Borne Diseases · Systemic Inflammatory Response Syndrome
Primary: Emax — 0.35 Maximum clearance rate (1/hour)
Phase 1 N=37 A Healthy Volunteer Safety Study of Pyronaridine Tetraphosphate Taken in Combination With Piperaquine Tetraphosphate
Healthy
Primary: The Incidence, Severity and Relationship of Treatment-Emergent Adverse Events (TEAEs). — 10; 7; 4; 5 participants
Phase 1 N=24 Safety, Tolerability and Antimalarial Activity of Single Doses of OZ439 and PQP
Malaria
Primary: Characterize the PK/PD Relationship Between OZ439 and PQP Plasma Concentrations (Cmax) — 0.2582; 0.4145; 0.8829; 0.6835 ng/L
Phase 3 N=1,272 Pyronaridine Artesunate (3:1) Versus Coartem® in P Falciparum Malaria Patients
Malaria
Primary: PCR-Corrected Adequate Clinical and Parasitological Response (ACPR) Rate on Day 28 — 99.5; 99.2 percentage of subjects — p=0.578
N/A N=1,000 Validation of RealAmp Method for the Diagnosis of Malaria in Endemic Areas of Brazil
Malaria Diagnosis
Primary: Malaria Diagnosis Using RealAmp and Microscopy. — 42; 153; 0; 1 Participants